Vaxart To Meet With FDA In Mid-2024 To Evaluate Clinical Data And Discuss Next Steps For Its Norovirus Program; Anticipates Cash Runway Into Late Q4 Of 2024

Benzinga ·  May 14 04:14

These data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge study. Expects to initiate Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024.

Cash, cash equivalents and investments totaled $36.7 million as of March 31, 2024. The Company did not receive any cash payments from BARDA in the first quarter of 2024. Currently, Vaxart anticipates cash runway into late fourth quarter of 2024.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment